FDA Approves Arcutis Zoryve (Roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Individuals Age 12 and Older
Arcutis Biotherapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for ZORYVE (roflumilast) cream 0.3% for...